BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
1/21/2022 8:16:14 AM | Browse: 399 | Download: 820
 |
Received |
|
2021-06-17 14:59 |
|
Peer-Review Started |
|
2021-06-17 15:05 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2021-08-18 02:27 |
|
Revised |
|
2021-08-30 08:15 |
|
Second Decision |
|
2021-12-06 03:29 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2021-12-08 06:10 |
|
Articles in Press |
|
2021-12-08 06:10 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2022-01-18 04:31 |
|
Publish the Manuscript Online |
|
2022-01-21 08:16 |
| ISSN |
1948-5182 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Cardiac & Cardiovascular Systems |
| Manuscript Type |
Review |
| Article Title |
Is there a role of lipid-lowering therapies in the management of fatty liver disease?
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Ismini Tzanaki, Aris P Agouridis and Michael S Kostapanos |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Michael S Kostapanos, MD, MRCP, PhD, Consultant Physician-Scientist, General Medicine, Addenbrooke's Hospital, Cambridge University Hospitals, Hill's Road, Cambridge CB20QQ, United Kingdom. mk828@medschl.cam.ac.uk |
| Key Words |
Non-alcoholic fatty liver; Non-alcoholic steatohepatitis; Statin; Ezetimibe; Fibrates; ω-3 fatty acids; Bile acid resins |
| Core Tip |
Statins may be beneficial against NAFLD/NASH in association with their cholesterol-lowering efficacy as well as their anti-inflammatory, antioxidant and anti-fibrotic actions. Elimination of hepatic steatosis, inflammation and fibrosis was noted with statin use in the clinical setting of NAFLD/NASH. Experimental evidence suggests that ezetimibe has similar benefits to statins against NAFLD/NASH. However, ezetimibe was beneficial only against hepatic steatosis, but not against inflammation or fibrosis in NAFLD patients. Despite their promising mechanistic potential against NAFLD/NASH through PPARα activation benefits of fibrates on liver outcomes have not been established in clinical studies. Ample heterogeneous evidence suggests benefits of ω-3 fatty acids against hepatic steatosis, but not inflammation or fibrosis. |
| Publish Date |
2022-01-21 08:16 |
| Citation |
Tzanaki I, Agouridis AP, Kostapanos MS. Is there a role of lipid-lowering therapies in the management of fatty liver disease? World J Hepatol 2022; 14(1): 119-139 |
| URL |
https://www.wjgnet.com/1948-5182/full/v14/i1/119.htm |
| DOI |
https://dx.doi.org/10.4254/wjh.v14.i1.119 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
